GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCH) » Definitions » Total Receivables

Envoy Medical (Envoy Medical) Total Receivables : $0.22 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical Total Receivables?

Envoy Medical's Total Receivables for the quarter that ended in Mar. 2024 was $0.22 Mil.


Envoy Medical Total Receivables Historical Data

The historical data trend for Envoy Medical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical Total Receivables Chart

Envoy Medical Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
0.09 0.04 0.25

Envoy Medical Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only - 0.06 1.11 0.25 0.22

Envoy Medical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Envoy Medical Total Receivables Related Terms

Thank you for viewing the detailed overview of Envoy Medical's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Envoy Medical (Envoy Medical) Business Description

Traded in Other Exchanges
N/A
Address
4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is focused on designing, developing, and marketing fully implantable medical devices that improve hearing. The Company's first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue the development of a cochlear implant.